BACKGROUND: Evidence suggests that insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3, also known as IMP3) represents a promising cancer biomarker. However, the clinical, pathological, molecular and prognostic features of IGF2BP3-positive colorectal cancers remain uncertain. MATERIALS AND METHODS: We evaluated IGF2BP3 expression by immunohistochemistry in 671 rectal and colon cancer cases that form part of a molecular pathological epidemiology database. Cox proportional hazards regression models were used to compute mortality hazard ratio (HR), adjusting for clinical, pathological and molecular features, including microsatellite instability, the CpG island methylator phenotype, LINE-1 methylation and KRAS, BRAF and PIK3CA mutations. RESULTS: Among 671 colorectal cancers, 234 (35%) tumours were positive for IGF2BP3. In contrast, normal colorectal epithelium was negative for IGF2BP3 in all 403 specimens of normal mucosa adjacent to carcinoma. IGF2BP3 positivity was associated with poor differentiation (p=0.0003), stage III-IV disease (p=0.0081), BRAF mutation (p=0.031), and LINE-1 hypomethylation (p=0.020). IGF2BP3 positivity was significantly associated with shorter colorectal cancer-specific [log-rank p<0.0001; multivariate HR, 1.37; 95% confidence interval (CI), 1.02-1.84] and overall survival (log-rank p=0.0004; multivariate HR, 1.32; 95% CI, 1.05-1.66). CONCLUSIONS: IGF2BP3 expression in colorectal cancer is associated with adverse clinical outcome. Our findings support a role for IGF2BP3 as a diagnostic and/or prognostic biomarker in colorectal cancer.
BACKGROUND: Evidence suggests that insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3, also known as IMP3) represents a promising cancer biomarker. However, the clinical, pathological, molecular and prognostic features of IGF2BP3-positive colorectal cancers remain uncertain. MATERIALS AND METHODS: We evaluated IGF2BP3 expression by immunohistochemistry in 671 rectal and colon cancer cases that form part of a molecular pathological epidemiology database. Cox proportional hazards regression models were used to compute mortality hazard ratio (HR), adjusting for clinical, pathological and molecular features, including microsatellite instability, the CpG island methylator phenotype, LINE-1 methylation and KRAS, BRAF and PIK3CA mutations. RESULTS: Among 671 colorectal cancers, 234 (35%) tumours were positive for IGF2BP3. In contrast, normal colorectal epithelium was negative for IGF2BP3 in all 403 specimens of normal mucosa adjacent to carcinoma. IGF2BP3 positivity was associated with poor differentiation (p=0.0003), stage III-IV disease (p=0.0081), BRAF mutation (p=0.031), and LINE-1 hypomethylation (p=0.020). IGF2BP3 positivity was significantly associated with shorter colorectal cancer-specific [log-rank p<0.0001; multivariate HR, 1.37; 95% confidence interval (CI), 1.02-1.84] and overall survival (log-rank p=0.0004; multivariate HR, 1.32; 95% CI, 1.05-1.66). CONCLUSIONS: IGF2BP3 expression in colorectal cancer is associated with adverse clinical outcome. Our findings support a role for IGF2BP3 as a diagnostic and/or prognostic biomarker in colorectal cancer.
Authors: Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs Journal: Gut Date: 2008-10-02 Impact factor: 23.059
Authors: Di Lu; Xiaofang Yang; Naomi Y Jiang; Bruce A Woda; Qin Liu; Karen Dresser; Arthur M Mercurio; Kenneth L Rock; Zhong Jiang Journal: Am J Surg Pathol Date: 2011-11 Impact factor: 6.394
Authors: Jeanette E Eckel-Passow; Christine M Lohse; Yuri Sheinin; Paul L Crispen; Christopher J Krco; Eugene D Kwon Journal: Diagn Pathol Date: 2010-07-07 Impact factor: 2.644
Authors: Xiaoyun Liao; Teppei Morikawa; Paul Lochhead; Yu Imamura; Aya Kuchiba; Mai Yamauchi; Katsuhiko Nosho; Zhi Rong Qian; Reiko Nishihara; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino Journal: Clin Cancer Res Date: 2012-02-22 Impact factor: 12.531
Authors: Federica Panebianco; Lindsey M Kelly; Pengyuan Liu; Shan Zhong; Sanja Dacic; Xiaosong Wang; Aatur D Singhi; Rajiv Dhir; Simion I Chiosea; Shih-Fan Kuan; Rohit Bhargava; David Dabbs; Sumita Trivedi; Manoj Gandhi; Rachel Diaz; Abigail I Wald; Sally E Carty; Robert L Ferris; Adrian V Lee; Marina N Nikiforova; Yuri E Nikiforov Journal: Proc Natl Acad Sci U S A Date: 2017-02-13 Impact factor: 11.205
Authors: Mary K Townsend; Hugues Aschard; Immaculata De Vivo; Karin B Michels; Peter Kraft Journal: Am J Public Health Date: 2016-07-26 Impact factor: 9.308
Authors: Kathryn E Hamilton; Felicite K Noubissi; Prateek S Katti; Christopher M Hahn; Sonya R Davey; Emma T Lundsmith; Andres J Klein-Szanto; Andrew D Rhim; Vladimir S Spiegelman; Anil K Rustgi Journal: Carcinogenesis Date: 2013-06-12 Impact factor: 4.944
Authors: Hanane Ennajdaoui; Jonathan M Howard; Timothy Sterne-Weiler; Fereshteh Jahanbani; Doyle J Coyne; Philip J Uren; Marija Dargyte; Sol Katzman; Jolene M Draper; Andrew Wallace; Oscar Cazarez; Suzanne C Burns; Mei Qiao; Lindsay Hinck; Andrew D Smith; Masoud M Toloue; Benjamin J Blencowe; Luiz O F Penalva; Jeremy R Sanford Journal: Cell Rep Date: 2016-05-19 Impact factor: 9.423